Esperion Therapeutics (ESPR) Other Gross PP&E Adjustments (2018 - 2025)
Historic Other Gross PP&E Adjustments for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$3.3 million.
- Esperion Therapeutics' Other Gross PP&E Adjustments rose 4656.06% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 4656.06%. This contributed to the annual value of -$29.2 million for FY2024, which is 417.08% down from last year.
- Per Esperion Therapeutics' latest filing, its Other Gross PP&E Adjustments stood at -$3.3 million for Q3 2025, which was up 4656.06% from -$4.2 million recorded in Q2 2025.
- Over the past 5 years, Esperion Therapeutics' Other Gross PP&E Adjustments peaked at -$730000.0 during Q3 2022, and registered a low of -$29.2 million during Q4 2024.
- For the 5-year period, Esperion Therapeutics' Other Gross PP&E Adjustments averaged around -$8.6 million, with its median value being -$4.3 million (2021).
- Per our database at Business Quant, Esperion Therapeutics' Other Gross PP&E Adjustments skyrocketed by 8487.16% in 2022 and then crashed by 56325.58% in 2024.
- Over the past 5 years, Esperion Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at -$21.9 million in 2021, then fell by 12.07% to -$24.6 million in 2022, then fell by 14.3% to -$28.1 million in 2023, then dropped by 4.17% to -$29.2 million in 2024, then skyrocketed by 88.63% to -$3.3 million in 2025.
- Its Other Gross PP&E Adjustments was -$3.3 million in Q3 2025, compared to -$4.2 million in Q2 2025 and -$5.0 million in Q1 2025.